To the press room
Update 3:50 PM Pacific Time-Friday, October 30, 2020
For safety reasons, “Regeneron” has suspended trials on the most ill patients.
According to reports on Friday, the pharmaceutical company decided to stop providing antibody drugs to coronavirus patients on ventilators or patients receiving large amounts of oxygen.
Announcing the latest developments of #COVID19 patients hospitalized in the ongoing Regeneron research antibody mixture P2/3 study: https://t.co/6maNUOpruE pic.twitter.com/4xG0gg0qbT
-Regeneron (@Regeneron) October 30, 2020
However, the company said it will continue to conduct trials on patients with milder conditions.
This is after another pharmaceutical company, Eli Lilly, ended its trial on hospitalized patients on Monday after determining that the severe coronavirus was invalid.